Activin A more prominently regulates muscle mass in primates than does GDF8
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Growth and differentiation factor 8 (GDF8) is a TGF-β superfamily member, and negative regulator of skeletal muscle mass. GDF8 inhibition results in prominent muscle growth in mice, but less impressive hypertrophy in primates, including man. Broad TGF-β inhibition suggests another family member negatively regulates muscle mass, and its blockade enhances muscle growth seen with GDF8-specific inhibition. Here we show that activin A is the long-sought second negative muscle regulator. Activin A specific inhibition, on top of GDF8 inhibition, leads to pronounced muscle hypertrophy and force production in mice and monkeys. Inhibition of these two ligands mimics the hypertrophy seen with broad TGF-β blockers, while avoiding the adverse effects due to inhibition of multiple family members. Altogether, we identify activin A as a second negative regulator of muscle mass, and suggest that inhibition of both ligands provides a preferred therapeutic approach, which maximizes the benefit:risk ratio for muscle diseases in man.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and others have previously demonstrated that growth differentiation factor-8 (GDF8; also known as myostatin) and activin A (ActA) are the two major ligands mediating the muscle-minimization actions of ActRIIA/B receptors22,26–30.”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“combining these blocking antibodies results in much greater increases in muscle than either of the antibodies individually, with dual blockade matching the muscle growth induced by broader ActRIIA/B pathway blockade in both mice and non-human primates (NHPs)28,31”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“The function of MSTN in muscle is at least partially redundant with that of another TGF-β family member, activin A (13–16).”
From Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight (2020) · cites this paper as [16]
In the citing paper
“However, this effect on glucose tolerance was not observed in mice treated with antibodies specific to two ActRII ligands, GDF-8 and activin A, suggesting the potential involvement of additional ActRII ligands in the regulation of glucose homeostasis [36].”
From Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (2024) · cites this paper as [36]
In the citing paper
“Notably, administration of a soluble ActRIIB fragment impaired glucose tolerance in lean mice, which was correlated with increased spleen and pancreas weights [36].”
From Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (2024) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Loffredo, F. S., Steinhauser, M. L., Jay, S. M., Gannon, J., Pancoast, J. R., Yalamanchi, P., Sinha, M., Dall’Osso, C., Khong, D., Shadrach, J. L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.015 · Cited by 948
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 940
Functional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831
Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle
Sinha, M., Jang, Y. C., Oh, J., Khong, D., Wu, E. Y., Manohar, R., Miller, C., Regalado, S. G., Loffredo, F. S., Pancoast, J. R., et al. (2014) · Science · doi:10.1126/science.1251152 · Cited by 824
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
David, L., Mallet, C., Mazerbourg, S., Feige, J.-J., & Bailly, S. (2007) · Blood · doi:10.1182/blood-2006-07-034124 · Cited by 708
Research works printed but not linked: 1
- Schwarzkopf, M., Coletti, D., Marazzi, G. & Sassoon, D. Chronic p53 leads to skeletal muscle atrophy and muscle stem cell perturbation. Basic Appl. Myol. 18, 131–138 (2008).
Cited by
Items 101–184 of 184
Vaughan, D., Ritvos, O., Mitchell, R., Kretz, O., Lalowski, M. M., Amthor, H., Chambers, D., Matsakas, A., Pasternack, A. H., Collins‐Hooper, H., et al. (2020) · European Journal of Translational Myology · doi:10.4081/ejtm.2019.8737 · Cited by 12
Brent, M. B., Lodberg, A., Bromer, F. D., van der Eerden, B. C. J., Eijken, M., Brüel, A., & Thomsen, J. S. (2020) · Bone · doi:10.1016/j.bone.2020.115692 · Cited by 12
Possible Role of Activin in the Adiponectin Paradox-Induced Progress of Alzheimer’s Disease
Hashimoto, M., Ho, G. J., Sugama, S., Takenouchi, T., Waragai, M., Sugino, H., Inoue, S., & Masliah, E. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210206 · Cited by 12
“Also, muscle mass is negatively regulated by activin in primates, suggesting that activin might be involved in promoting sarcopenia [26].”
BackgroundThe Role of TGF-β, Activin and Follistatin in Inflammatory Bowel Disease
Esfahani, N. H., & Day, A. S. (2023) · Gastrointestinal Disorders · doi:10.3390/gidisord5020015 · Cited by 12
In chronic kidney disease altered cardiac metabolism precedes cardiac hypertrophy
Williams, M. J., Halabi, C. M., Patel, H. M., Joseph, Z., McCommis, K. S., Weinheimer, C. J., Kovács, A. D., Lima, F., Finck, B. N., Malluche, H. H., et al. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00416.2023 · Cited by 11
Emerging Interventions for Elderly Patients—The Promise of Regenerative Medicine
Miller, R. R., & Roubenoff, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1272 · Cited by 12
“Activin A is another ligand that signals through the ActRII receptor pathway and has been found to have a greater effect on muscle mass in primates than myostatin.(33) Study participants received a single dose of either placebo or one of three dose levels of the combination of the two antibodies.”
BackgroundHarish, P., Forrest, L., Herath, S., Dickson, G., Malerba, A., & Popplewell, L. J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00184 · Cited by 12
“Alternatively, other molecules which negatively regulate muscle mass (such as activin A), might reduce the efficacy of myostatin knockdown in this older cohort (Latres et al., 2017).”
BackgroundSzabó, Z., Vainio, L., Lin, R., Swan, J., Hulmi, J. J., Rahtu‐Korpela, L., Serpi, R., Laitinen, M., Pasternack, A. H., Ritvos, O., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201903074rr · Cited by 12
Myokines and interorgan crosstalk: bridging exercise to health promotion and disease prevention
Ha, J., Sung, S., & Kim, H. (2025) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2448218.109 · Cited by 10
Ma, L., Duan, C., Yang, Z., Ding, J., Liu, S., Yue, Z., & Guo, B. (2019) · Bone · doi:10.1016/j.bone.2019.03.036 · Cited by 10
Cawthon, P. M., Patel, S., Newman, A. B., Bhasin, S., Peng, L., Tracy, R. P., Kizer, J. R., Lee, S., Ferrucci, L., Ganz, P., et al. (2023) · The Journals of Gerontology Series A · doi:10.1093/gerona/glad045 · Cited by 11
Richman, J. A., Davis, L. R., & Phelps, M. (2024) · Genome Biology and Evolution · doi:10.1093/gbe/evae096 · Cited by 10
“Activin A is known to be commonly expressed in these tissues in vertebrates, since it is a multifunctional signaling molecule with key roles in reproductive tissues (Hsueh et al. 1987), skeletal muscle (Latres et al. 2017), and embryonic development (Vassalli et al. 1994).”
BackgroundProteomics analysis of C2C12 myotubes treated with atrophy inducing cancer cell‐derived factors
Marzan, A. L., Chitti, S. V., Gummadi, S., Kang, T., Ang, C., & Mathivanan, S. (2023) · PROTEOMICS · doi:10.1002/pmic.202300020 · Cited by 10
“Indeed, it is well documented that activin acts as a negative regulator of muscle growth [34, 35].”
BackgroundSkeletal muscle growth to combat diabetes and obesity: the potential role of muscle‐secreted factors
Sammut, M. J., Thorne, B. R., & Melling, C. W. J. (2025) · Obesity · doi:10.1002/oby.24223 · Cited by 8
“Unlike current appetite-suppressive weight loss drugs, bimagrumab blocks the actions of MSTN and activin A, which are negative regulators of muscle mass [113, 114].”
Ahmadi-Harchegani, F., Tobin, R. A., Degan, C., Naveed, A., Guglieri, M., Jiménez-Requena, A., de Vries, S. I., Szigyarto, C. A., Spitali, P., Tsonaka, R., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-23758-6 · Cited by 9
Egerman, M. A., Zhang, Y., Donné, R., Xu, J., Gadi, A., McEwen, C., Salmon, H. A., Xiong, K., Bai, Y., Germino, M., et al. (2025) · Skeletal Muscle · doi:10.1186/s13395-025-00373-7 · Cited by 9
“In contrast, global Activin A knockouts are not viable; however, dual pharmacological blockade of Activin A and myostatin in adult animals results in more skeletal muscle mass than blockade of myostatin alone [14, 15].”
Self-citationNguyen, H. Q., Iskenderian, A., Ehmann, D. E., Jasper, P., Zhang, Z., Rong, H., Welty, D. F., & Narayanan, R. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12518 · Cited by 9
“found to be a second player in regulating muscle size and mass.(12) By including both activin and myostatin in a mechanistic model with their corresponding receptor occupancies, the model simulations (Figure 4a) showed that inhibiting activin and myostatin can reduce ActRIIB RO by additional 10% compared with only myo…”
BackgroundPham, T. C. P., Bojsen-Møller, K. N., Madsbad, S., Wojtaszewski, J. F. P., Richter, E. A., & Sylow, L. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-00664-7 · Cited by 8
Thevis, M., Walpurgis, K., Thomas, A., & Geyer, H. (2019) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2019.05.004 · Cited by 9
Emmert, M. E., Aggarwal, P., Shay‐Winkler, K., Lee, S., Goh, Q., & Cornwall, R. (2022) · eLife · doi:10.7554/elife.81121 · Cited by 9
Calluy, E., Malrechauffé, Y., Boretti, E., Heden, S. V., Sánchez‐Rodríguez, D., Chan, Y. M., Cavalier, E., Ladang, A., Reginster, J. Y., Douxfils, J., et al. (2026) · Aging Cell · doi:10.1111/acel.70361 · Cited by 7
“Second, myo-statin and activin A act as catabolites, inhibiting muscle growth and increasing muscle breakdown (Esther Latres et al. 2017).”
Myostatin inhibitory peptides in sports drug testing
Walpurgis, K., Agricola, J., Thomas, A., & Thevis, M. (2023) · Drug Testing and Analysis · doi:10.1002/dta.3473 · Cited by 7
Omosule, C. L., Joseph, D., Weiler, B., Gremminger, V. L., Silvey, S., Lafaver, B. N., Jeong, Y., Kleiner, S., & Phillips, C. L. (2023) · JBMR Plus · doi:10.1002/jbm4.10753 · Cited by 7
“The observation that the Combo treatment more robustly impacted muscle and fat masses in mice emphasizes the combined roles of myostatin and activin A in postnatal muscular and adipose tissue regulation in mice.((18)) Neither Mstn-Ab nor ActA-Ab effected significant changes in absolute or relative inguinal tissue, gon…”
BackgroundInfluentialInhibition of the activin receptor signaling pathway: A novel intervention against osteosarcoma
Meier, D., Lodberg, A., Gvozdenovic, A., Pellegrini, G., Neklyudova, O., Born, W., Fuchs, B., Eijken, M., & Botter, S. M. (2020) · Cancer Medicine · doi:10.1002/cam4.3581 · Cited by 7
“FST∆HBS-hFc 105 (73-152) IC50 pM (95% CI) FST315 49 (33-73)”
Ligand-specific regulation of a binary enhancer code dictating cellular senescence
Suter, T., Friedman, M. J., Tazearslan, C., Merkurjev, D., Ohgi, K., Meluzzi, D., Rosenfeld, M. G., & Suh, Y. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2506321122 · Cited by 5
Baik, J., & Lee, Y. (2025) · Journal of Bone Metabolism · doi:10.11005/jbm.25.919 · Cited by 6
“[82] This finding is supported by clinical trials, where combined treatment with trev-ogrumab (anti-MSTN) and garetosmab (anti-activin A) increased total body muscle volume and reduced fat mass compared with placebo or either antibody alone.”
Bojsen-Møller, K. N., Svane, M. S., Jensen, C. Z., Kjeldsen, S. A. S., Holst, J. J., Albrechtsen, N. J. W., & Madsbad, S. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00396.2020 · Cited by 5
GDF8 Contributes to Liver Fibrogenesis and Concomitant Skeletal Muscle Wasting
Culver, A. E., Hamang, M., Wang, Y., Jiang, H., Yanum, J. A., White, E., Gawrieh, S., Vuppalanchi, R., Chalasani, N., Dai, G., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11071909 · Cited by 6
“Activin A was included in this study because it has been suggested by others to be the most likely ActRIIB receptor ligand responsible for muscle mass loss [35].”
MethodRichman, J. A., & Phelps, M. (2024) · Marine Biotechnology · doi:10.1007/s10126-024-10345-5 · Cited by 5
“Both myostatin and activin A are negative regulators of skeletal muscle growth in mammals (Latres et al. 2017).”
Moqaddam, M. A., Nemati, M., Dara, M. M., Hoteit, M., Sadek, Z., Ramezani, A., Rand, M. K., Daloii, A. A., Pashaei, Z., Almaqhawi, A., et al. (2024) · Nutrients · doi:10.3390/nu16172857 · Cited by 6
Patel, J., Ho, V., Tran, T., Teshome, B., & Rai, V. (2025) · Biomedicines · doi:10.3390/biomedicines13122994 · Cited by 4
“Neutralizing activin A with a specific antibody accelerates muscle repair and functional recovery by promoting a more efficient clearance of damaged tissue and enhancing the activation of muscle precursor cells [31].”
Herman, J. L., Dornbos, P., Landheer, K., Geraghty, B. J., Egerman, M. A., Phan, D., Germino, M., Mastaitis, J. W., Walls, J. R., Lotta, L. A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70422-2 · Cited by 8
“…2 – 4% increases in muscle mass, the combination of anti-myostatin and anti-Activin A (ActA) antibodies resulted in seemingly comparable muscle gain as seen with Bimagrumab, indicating that myostatin and ActA are the dominant ActRII-binding ligands regulating skeletal muscle mass in humans 24,25 .”
Self-citationKaspiris, A., Vasiliadis, E. S., Tsalimas, G., Melissaridou, D., Lianou, I., Panagopoulos, F., Katzouraki, G., Vavourakis, M., Kolovos, I., Savvidou, O. D., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123484 · Cited by 4
“Moreover, a study by Goh et al. [65], examining skeletal phenotypes in activin receptor (ACVR) type 2A knock-out mice, showed increased trabecular bone, suggesting a direct and negative regulation of activin signaling on bone mass, too.”
BackgroundVaughan, D., Kretz, O., Alqallaf, A., Mitchell, R., der Heide, J. L. V., Vaiyapuri, S., Matsakas, A., Pasternack, A. H., Collins‐Hooper, H., Ritvos, O., et al. (2020) · European Journal of Translational Myology · doi:10.4081/ejtm.2020.8904 · Cited by 4
Han, X., Møller, L. L. V., Groote, E. D., Bojsen-Møller, K. N., Davey, J., Henríquez-Olguin, C., Li, Z., Knudsen, J. R., Jensen, T. E., Madsbad, S., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/568097 · Cited by 4
Lien, W., Yu, Y., Liang, Y., Wang, C., Lin, Y., Chang, H., Lin, F., & Wang, H. (2025) · Small Science · doi:10.1002/smsc.202500208 · Cited by 3
Beavers, K. M., Serra, M. C., Weaver, A. A., & Houston, D. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00035-6 · Cited by 6
The Future of Drugs in Sarcopenia
Zazzara, M. B., Penfold, R., & Onder, G. (2021) · Practical issues in geriatrics · doi:10.1007/978-3-030-80038-3_14 · Cited by 4
Morel, J., Pignard, A. S., Castells, J., Allibert, V., Hatimi, L., Buhot, B., Velarde, M., Durieux, A., & Freyssenet, D. G. (2024) · The Journal of Physiology · doi:10.1113/jp284973 · Cited by 2
“Activin A, another member of this family, activates canonical SMAD2/3 signalling with comparable potencies and efficacy as myostatin does (Latres et al., 2017).”
BackgroundCadena, S. M., Bogdanovich, S., Khurana, T. S., Pullen, A. E., Pearsall, R. S., Curran, E., Faucette, R., Lane, J., Seehra, J. S., Lachey, J. L., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0342666 · Cited by 2
“It has been reported that circulating activin A levels in monkeys and humans are 3–4-fold higher than mice and rats [21], suggesting that myostatin specific treatments that appear promising in mice are not likely to be as impactful in humans.”
InfluentialBreen, D. M., Joaquim, S., Paulhus, B. L., Bennett, D., Bernardo, B. L., Collins, S. M., Esquejo, R. M., Kim-Muller, J. Y., Laura, L., Peloquin, M., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70312 · Cited by 2
“Since mice predominantly depend on myostatin as the primary negative regulator of ActRIIB-dependent muscle mass [19], anti-myostatin antibody was selected for the mechanistic combination experiments.”
Prospects for assessing the biological and immunological age of a person by blood factors
Kurgan, N. D., Panova, E. I., Silakova, L. V., Каганский, А. М., & Александрович, Р. С. (2021) · Science and Innovations in Medicine · doi:10.35693/2500-1388-2021-6-4-19-39 · Cited by 2
“В то же время увеличение катаболических факторов, таких как GDF8, активин A, приводят к замедлению регенерации тканей сердца и скелетных мышц, снижая способность к регенерации в ответ на травматическое воздействие [64, 65].”
Пальцын, А. А. (2018) · Zhurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia» · doi:10.25557/0031-2991.2018.02.113-121 · Cited by 2
Postprandial secretion of follistatin after gastric bypass surgery and sleeve gastrectomy
Richter, M. M., Svane, M. S., Kristiansen, V. B., Holst, J. J., Madsbad, S., & Bojsen-Møller, K. N. (2023) · Peptides · doi:10.1016/j.peptides.2023.170978 · Cited by 2
“In humans, activin A may be more important than myostatin in regulating muscle mass [33].”
Obesity, Myokines, and Metabolic Health
Malandrino, N., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_56 · Cited by 2
Association and causality between diabetes and activin A: a two-sample Mendelian randomization study
Wang, M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1414585 · Cited by 1
Shi, A., Hillege, M. M. G., Noort, W., Offringa, C., Offringa, C., Tim, F., Hoogaars, W. M. H., Hoogaars, W. M. H., & Jaspers, R. T. (2026) · Communications Biology · doi:10.21203/rs.3.rs-5136404/v1 · Cited by 1
van Krimpen, S. J., Simons, S. O., Schols, A. M. W. J., LANGEN, R. C. J., & Gosker, H. R. (2026) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2026.2620144 · Cited by 2
Protein therapeutics in sports drug testing: past, present and future
Walpurgis, K., Sakellariou, P., Thomas, A., & Thevis, M. (2026) · Expert Review of Proteomics · doi:10.1080/14789450.2026.2629979 · Cited by 1
“A study published by Latres and coworkers in 2017 [176] showed that the circulating MSTN levels in mice are significantly higher than in humans while at the same time the concentrations of ActA are much lower.”
Activin A secretion by muscle-repairing macrophages induces heterotopic ossification in mice
Yin, W., Okamoto, K., Terashima, A., Pluemsakunthai, W., Ono, T., Ito-Kureha, T., Akira, S., Hashizume, Y., Baron, R., Ueha, S., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci193797 · Cited by 2
“However, prolonged inhibition of activin A with a neutralizing antibody has been shown to promote muscle growth in both muscle hypertrophy and cardiotoxin-in-duced muscle injury models (27, 28).”
Song, T., Zhang, X., Wang, G., Liu, G., Mustafa, S. B., Shahzad, K., Chen, X., Zhang, M., Zeng, X., Liu, M., et al. (2026) · Italian Journal of Animal Science · doi:10.1080/1828051x.2026.2625495 · Cited by 1
Circulating plasma follistatin follows a 24-hour rhythm in healthy young males
Zilstorff, D. B., Sennels, H. P., Jørgensen, H. L., Albrechtsen, N. J. W., & Richter, M. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag121 · Cited by 1
Lisco, G., Tullio, A. D., Disoteo, O., Dicorato, P., Tortora, A., Geronimo, V. D., & Triggiani, V. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10033-w · Cited by 1
“…[118, 119], human physiology exhibits equivocal responses due to differential ligand-receptor affinities (e.g., activin A predominance in primates over growth differentiating factor 8) [ 120] and compensatory pathways such as IGF-1 resistance in obesity, limiting translatability of results.”
Periodontitis induces skeletal muscle atrophy by increasing circulating levels of activin A.
Shim, W., Suh, J., Kim, H. K., Kim, N.-J., Kim, Y., Jeong, Y. T., Kim, M.-S., Lee, S., & Lee, Y. (2026) · Nature Communications · doi:10.1038/s41467-026-72766-1 · Cited by 1
“Activin A is a potent negative regulator of muscle mass and a key contributor to muscle wasting in cancer cachexia 16,17,23 .”
Prokopidis, K., Deane, C. S., Baoubbou, Z., & Beaudart, C. (2026) · The Journals of Gerontology Series A · doi:10.1093/gerona/glag140 · Cited by 1
Hu, R., Zhang, X., Hu, L., Li, X., Hu, Q., & Jin, H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1868285 · Cited by 2
Vaughan, D., Mitchell, R., Kretz, O., Chambers, D. J., Lalowski, M. M., Amthor, H., Ritvos, O., Pasternack, A. H., Matsakas, A., Vaiyapuri, S., et al. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.047555 · Cited by 1
“This line of thinking has been supported in primate studies, which reported sActRIIB-induced changes in the spleen and pancreas and glucose homeostasis (Latres et al., 2017).”
ResultAnabolic and anticatabolic agents in kidney disease and kidney failure
Chiang, J. M., & Johansen, K. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818540-7.00040-9 · Cited by 1
Shi, A., Hillege, M. M., Noort, W., Offringa, C., Wu, G., Forouzanfar, T., Hoogaars, W. M. H., Wüst, R. C. I., & Jaspers, R. T. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.30.555466 · Cited by 1
Schlansky, B. L., & Farsad, K. (2022) · Digestive Disease Interventions · doi:10.1055/s-0041-1742214
Role of SMAD2 and SMAD3 on Adipose Tissue Development and Function
Kumari, R. (2021) · doi:10.21007/etd.cghs.2021.0550 · Cited by 1
Omosule, C. L. (2021) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/90078
Obesity, Myokines, and Metabolic Health
Malandrino, N., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_56-1
Khalil, H. A., El-Yazbi, A. F., El‐Kimary, E. I., & Belal, T. S. (2024) · Journal of Advanced Pharmaceutical Sciences · doi:10.21608/japs.2024.286122.1023
Gu, X., Wang, X., Yang, Y., Guan, K., Chang, H.-C., Liu, D., Wang, W., Wu, T., He, P., Wang, J., et al. (2024) · Clinical and Translational Discovery · doi:10.1002/ctd2.70019
Suh, J., Baik, J.-S., & Lee, Y. (2025) · Journal of Bone Metabolism · doi:10.11005/jbm.25.915
Grunow, J. J., Reiher, K., Carbon, N. M., Engelhardt, L. J., Mai, K., Koch, S., Schefold, J. C., Z'Graggen, W. J., Schaller, S. J., Fielitz, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20428494
Tulonen, M. (2018) · Jyväskylä University Digital Archive (University of Jyväskylä)
Mansoor, M. A. M., Ashiqueali, S. A., Alam, M. T., Lijeron-Herrera, F., Zhu, X., Trivedi, J., Lasseter, A., Schneider, A., Flores, L., Wang, H., et al. (2026) · GeroScience · doi:10.1007/s11357-026-02207-w
“The manipulation of muscle growth has gained sig-nification traction in the past decade [19–25].”
Identification of new levers to fight muscle atrophy : benefit of the hibernating brown bear model
Cussonneau, L. (2022) · theses.fr (ABES) · doi:10.70675/1a11a81bzf829z4ba2zba9az6f3f4841c773
Myokines in cancer: bridging molecular mechanisms to biomarker discovery and therapeutic innovation
Zhang, H., Fu, D., Yue, M., Cheng, F., Jiang, Y., Zhao, J., Wang, W., Deng, S., Tian, D., Jin, G., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1751316
“Myostatin expression and biological activity were found to be up-regulated in experimental cancer cachexia in related research (25).”
Morito, K., Nishikawa, N., Hitachi, K., Tamaki, R., Nishikawa, M., Hayashi, Y., Tsuchida, K., & Takayama, K. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00124
p38MAP kinase regulates senescence in human iPS-derived myocytes
Sato, H., Arakane, M., Mizuno, Y., Sasaki, T., Sakurai, H., Kamihira, M., Enomoto, A., Takafuji, K., Takaya, J., Suzuki, T., et al. (2026) · Aging · doi:10.18632/aging.206385
“In particular, INHBA and PAI-1 have been reported to be involved in muscle atrophy [27, 28].”
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
“Growth Differentiation Factor-8 (GDF8) and Activin A (ActA)-Blocking Antibodies GDF8 (or myostatin) and ActA have been reported as two major ligands that mediate the muscle-minimization actions of ActRIIA/B [182,183].”
Buccheri, E., Xourafa, A., Noto, M. D., Chiaramonte, R., Catalano, A., Castellino, P., Vecchio, M., & Gaudio, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177677
“Experimental inhibition of these ligands has been shown to induce muscle hypertrophy, reduce adiposity, enhance bone formation, and modify bone structure [34,35].”
Shim, J. H., Lee, J. Y., Han, J., & Kim, H. S. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00358
Durieux, A., Arnould, D., Velarde, M., Allibert, V., Chloé, P., Quentin, D., Esra, K., Sidney, C., Girard, E., Louise, C., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70338
GDF3 is an endogenous antagonist of the ActE-ALK7/ACVR2 pathway in adipocytesPreprint
Kotikalapudi, N., Ramachandran, D., Zhou, E. Y., Howard, J. A., Vieira, C. J., Chen, W., HSU, S., Shin, K. C., Naz, S., Jiang, Z. G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.18.752693
Bone in osteogenesis imperfecta: features and therapy
Brunetti, G. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1950969
Metadata
- Authors
- Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., Willer, T., Bai, Y., Hae Kim, J., Rafique, A., Jaspers, S., Stitt, T., Murphy, A. J., Yancopoulos, G. D., & Gromada, J.
- Affiliations
- Regeneron (United States) (US)
- Corresponding author
- Gromada, Jesper
- ORCID
- Venue
- Nature Communications
- Published
- 2017-04-28
- Volume
- 8
- Issue
- 1
- Pages
- 15153-15153
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5414365
- OpenAlex
- W2609426395
- Semantic Scholar
- 2e417ec4d417ebe167247c3466c130be75b2cef3
- Cited by
- 185
- References
- 65
- Citations by year
- 2026: 22 · 2025: 12 · 2024: 22 · 2023: 19 · 2022: 17 · 2021: 29 · 2020: 31 · 2019: 20 · 2018: 11 · 2017: 2
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Physical Performance
- Keywords
- activin A, myostatin, skeletal muscle mass, muscle hypertrophy, TGF-beta superfamily, muscle growth, muscle force production, primates
- MeSH terms
- Animals, Antibodies, Monoclonal, Dexamethasone, Humans, Hypertrophy, Isometric Contraction, Macaca fascicularis, Male, Mice, Inbred C57BL, Muscle Hypotonia, Body Mass Index, Mice, SCID, Muscle, Skeletal, Activins, Activin Receptors, Type II, Mice, Rats, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.